Alzheimer’s Disease: Early Identification and Future Therapeutic Landscape

Alzheimer’s disease (AD) is an irreversible, age-related neurodegenerative disorder characterized by gradual decline in understanding, memory, and ability to perform activities of daily living (ADL); accounting for 60% to 80% of all dementia. More than 5 million Americans are living with AD, which accounts for 60% to 80% of all dementia. and by 2050, this the number of Americans living with AD is projected to rise to 14 million. Despite this significant burden, the currently approved AD treatments are symptomatic drugs that do not stop or delay the disease progression, of the disease and there remains with no approved disease-modifying therapy. to treat patients with AD. The latest evidence of data from emerging AD treatments options suggests that early identification of AD patients is necessary to critical for optimize optimizing outcomes. Thus, neurologists, primary care physicians (PCPs), and other providers who care for these patients need education on strategies for the early identification and management of patients with AD. In this podcast series, expert clinicians discuss the latest advances regarding the early diagnosis and future therapeutic landscape of patients with AD.